Pfizer Inc. (PFE)

US — Healthcare Sector
Peers: ABBV  MRK  LLY  BMY  JNJ  AMGN  GILD 

Automate Your Wheel Strategy on PFE

With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PFE
  • Rev/Share 11.0067
  • Book/Share 15.9713
  • PB 1.5906
  • Debt/Equity 0.6785
  • CurrentRatio 1.2581
  • ROIC 0.0897

 

  • MktCap 143953568400.0
  • FreeCF/Share 1.9771
  • PFCF 12.8301
  • PE 18.2674
  • Debt/Assets 0.2946
  • DivYield 0.0671
  • ROE 0.0878

 

  • Rating B+
  • Score 3
  • Recommendation Neutral
  • P/E Score 2
  • DCF Score 5
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation PFE Cantor Fitzgerald -- Neutral -- $24 April 22, 2025
Resumed PFE BofA Securities -- Neutral -- $29 Dec. 10, 2024
Initiation PFE Bernstein -- Market Perform -- $32 Oct. 17, 2024

News

Is Pfizer Stock a Buy?
PFE
Published: April 03, 2025 by: The Motley Fool
Sentiment: Negative

Pfizer's (PFE 0.77%) share price has fallen more than the S&P 500 so far this year. The big pharma stock is nearly 60% below its high set in late 2022.

Read More
image for news Is Pfizer Stock a Buy?
2 Absurdly Cheap Stocks to Buy and Hold for Years
CMCSA, PFE
Published: April 03, 2025 by: The Motley Fool
Sentiment: Positive

Buying stock in great companies when they are dealing with some short-term issue that creates stock price weakness can set investors up for big gains down the road. As long as the business is still in good shape, adding it to your portfolio when it's trading at a sizable discount can look like a brilliant move in the future.

Read More
image for news 2 Absurdly Cheap Stocks to Buy and Hold for Years
PFE, MRK, LLY & Other Drug Stocks Down Amid Tariff Jitters
LLY, MRK, PFE
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Negative

Stocks of PFE, MRK, ABBV, LLY and others declined on Tuesday due to uncertainty surrounding Trump's proposed tariffs on pharma imports.

Read More
image for news PFE, MRK, LLY & Other Drug Stocks Down Amid Tariff Jitters
Proxy adviser ISS recommends Pfizer shareholders to vote against CEO compensation
PFE
Published: April 02, 2025 by: Reuters
Sentiment: Negative

Institutional Shareholder Services is recommending Pfizer's investors to reject a management proposal on annual compensation for CEO Albert Bourla and other executives, the proxy adviser said on Wednesday.

Read More
image for news Proxy adviser ISS recommends Pfizer shareholders to vote against CEO compensation
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
ABBV, AMGN, BMY, GILD, LLY, MRK, MRNA, PFE, VRTX
Published: April 01, 2025 by: CNBC
Sentiment: Negative

Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'

Read More
image for news Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views
BNTX, MRNA, NVAX, PFE
Published: March 31, 2025 by: Fast Company
Sentiment: Negative

Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration's (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Secretary Robert F. Kennedy (RFK) Jr. over his views on immunization.

Read More
image for news Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
PFE
Published: March 31, 2025 by: Zacks Investment Research
Sentiment: Positive

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Read More
image for news Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
Feds probe tip that Pfizer delayed announcing COVID vaccine's success until after 2020 election: report
PFE
Published: March 26, 2025 by: New York Post
Sentiment: Negative

The report said GSK's former head of vaccine development, Philip Dormitzer, who joined the company after working at rival Pfizer, had told his GSK colleagues about the delay.

Read More
image for news Feds probe tip that Pfizer delayed announcing COVID vaccine's success until after 2020 election: report
Here's Why Pfizer (PFE) Fell More Than Broader Market
PFE
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Negative

In the latest trading session, Pfizer (PFE) closed at $25.21, marking a -1.33% move from the previous day.

Read More
image for news Here's Why Pfizer (PFE) Fell More Than Broader Market
5 Large Drug Stocks to Watch as Industry Recovers
ABBV, BAYRY, NVO, NVS, PFE
Published: March 25, 2025 by: Zacks Investment Research
Sentiment: Positive

Industry Description

Read More
image for news 5 Large Drug Stocks to Watch as Industry Recovers
Pfizer Is a Dirt-Cheap High-Yield Stock, But Is It a Buy?
PFE
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive

Of late, pharmaceutical behemoth Pfizer Inc.'s PFE stock has struggled, but it remains a bargain with generous dividends. Its financials aren't in bad shape either.

Read More
image for news Pfizer Is a Dirt-Cheap High-Yield Stock, But Is It a Buy?
Pfizer Sells Remaining 7.3% Stake in Haleon for Around 3.3B
PFE
Published: March 20, 2025 by: Zacks Investment Research
Sentiment: Neutral

Pfizer divests its 7.3% remaining stake in Haleon to institutional investors and Haleon itself.

Read More
image for news Pfizer Sells Remaining 7.3% Stake in Haleon for Around 3.3B
3 Reasons Pfizer Stock Could Be a Steal of a Deal in 2025
PFE
Published: March 20, 2025 by: The Motley Fool
Sentiment: Positive

If you're looking for reasonably priced stocks to pick up right now, you shouldn't overlook Pfizer (PFE -0.50%). The pharmaceutical giant isn't as risky an investment as it may appear to be.

Read More
image for news 3 Reasons Pfizer Stock Could Be a Steal of a Deal in 2025
Pfizer to dispose of entire Haleon stake
HLN, HLN-WI, PFE
Published: March 18, 2025 by: Reuters
Sentiment: Neutral

Haleon shareholder Pfizer will dispose of its entire 7.3% stake in the British consumer healthcare group, a bookrunner said on Tuesday.

Read More
image for news Pfizer to dispose of entire Haleon stake
Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts
PFE
Published: March 18, 2025 by: Business Wire
Sentiment: Neutral

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, April 29, 2025. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's First Quarter 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Inf.

Read More
image for news Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts
3 High-Yield Dividend Stocks to Buy Before March Ends
CCI, ENB, PFE
Published: March 17, 2025 by: 24/7 Wall Street
Sentiment: Positive

These three dividend stocks are certainly worth considering for long-term investors seeking higher yields in this declining interest rate environment.

Read More
image for news 3 High-Yield Dividend Stocks to Buy Before March Ends
Calls of the Day: Invitation Homes, Pfizer and Roblox
INVH, PFE, RBLX
Published: March 13, 2025 by: CNBC Television
Sentiment: Neutral

The Investment Committee debate the latest Calls of the Day.

Read More
image for news Calls of the Day: Invitation Homes, Pfizer and Roblox
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial
ARVN, PFE
Published: March 11, 2025 by: Benzinga
Sentiment: Negative

Arvinas, Inc. ARVN and Pfizer Inc. PFE released topline results from the Phase 3 VERITAC-2 trial evaluating vepdegestrant monotherapy versus fulvestrant in adult patients with advanced or metastatic breast cancer.

Read More
image for news Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial
Pfizer: Undervalued Safe Haven In Risk-Off Market​
PFE
Published: March 11, 2025 by: Seeking Alpha
Sentiment: Positive

Pfizer remained flat while the S&P 500 dropped 2.25%, reinforcing its defensive strength in a risk-off market. CY24 revenue reached $63.6B (+6.7% YoY), with non-COVID sales growing 12%, exceeding expectations of 9%-11%. R&D pipeline advanced with 12 approvals, 7 pivotal study starts, and 8 Phase 3 readouts, boosting oncology and obesity treatments.

Read More
image for news Pfizer: Undervalued Safe Haven In Risk-Off Market​
Pfizer Stock Up Almost 6% in 3 Months: Time to Buy, Sell or Hold?
PFE
Published: March 10, 2025 by: Zacks Investment Research
Sentiment: Positive

Investors may stay invested in PFE stock to see how its new growth drivers perform.

Read More
image for news Pfizer Stock Up Almost 6% in 3 Months: Time to Buy, Sell or Hold?
Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors
JNJ, PFE
Published: March 07, 2025 by: Seeking Alpha
Sentiment: Neutral

Johnson & Johnson and Pfizer occupy leading positions in the healthcare sector. Each of them has advantages, as well as dark spots in the portfolio of drugs relative to the comparator. In this article you will find out who is more promising for long-term investors.

Read More
image for news Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors
Pfizer appoints James List to lead development of obesity medicines
PFE
Published: March 06, 2025 by: Reuters
Sentiment: Positive

Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, which includes development of cardiovascular and obesity medicines.

Read More
image for news Pfizer appoints James List to lead development of obesity medicines
Final Trades: Pfizer, Paychex and the JEPI
PAYX, PFE
Published: March 06, 2025 by: CNBC Television
Sentiment: Neutral

The Investment Committee debates their Final Trades.

Read More
image for news Final Trades: Pfizer, Paychex and the JEPI
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs
PFE, SMMT
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral

HONG KONG , Feb. 24, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with several of Pfizer's antibody drug conjugates (ADCs) across multiple solid tumor settings. "Rapidly developing novel mechanisms that go beyond what is currently available to patients and physicians is what we believe will make the most significant impact for those facing the greatest challenges from cancer today," noted …

Read More
image for news Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs
Pfizer names former FDA director Patrizia Cavazzoni as chief medical officer
PFE
Published: February 24, 2025 by: Reuters
Sentiment: Positive

Pfizer said on Monday former head of FDA's drug center, Patrizia Cavazzoni, will join the drugmaker as chief medical officer.

Read More
image for news Pfizer names former FDA director Patrizia Cavazzoni as chief medical officer
Pfizer: What The Summit Therapeutics Deal Brings
PFE, SMMT
Published: February 24, 2025 by: Seeking Alpha
Sentiment: Neutral

Pfizer: What The Summit Therapeutics Deal Brings

Read More
image for news Pfizer: What The Summit Therapeutics Deal Brings
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)
PFE
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral

PHILADELPHIA, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Berger Montague advises shareholders of Pfizer Inc. (“Pfizer” or the “Company”) (NYSE: PFE) about an investigation into Pfizer's Board of Directors for potential breaches of fiduciary duties to Pfizer and its shareholders in connection with the Company's marketing and sale of Depo-Provera.

Read More
image for news INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
NVO, PFE
Published: February 23, 2025 by: The Motley Fool
Sentiment: Positive

Buying quality stocks when they're unpopular can be very rewarding.

Read More
image for news Prediction: These Could Be the Best-Performing Value Stocks Through 2030
2 No-Brainer Healthcare Stocks to Buy With $500 Right Now
PFE, VRTX
Published: February 21, 2025 by: The Motley Fool
Sentiment: Positive

Looking for a good area in which to invest? Consider the healthcare sector.

Read More
image for news 2 No-Brainer Healthcare Stocks to Buy With $500 Right Now
Dividend Harvesting Portfolio Week 207: $20,700 Allocated, $2,010.09 In Projected Dividends
BST, MO, O, PDI, PFE, QQQI, STWD, UTG
Published: February 20, 2025 by: Seeking Alpha
Sentiment: Positive

The S&P 500 is up 3.96% YTD, and I predict it could reach 7,000 by the end of 2025. The Dividend Harvesting Portfolio reached a new milestone with a 28.65% ROI, generating $2,010.09 in forward annualized dividend income. I added to positions in Pfizer, Starwood Property Trust, and Reaves Utility Income Trust, focusing on undervalued stocks with strong dividend yields.

Read More
image for news Dividend Harvesting Portfolio Week 207: $20,700 Allocated, $2,010.09 In Projected Dividends

About Pfizer Inc. (PFE)

  • IPO Date 1972-06-01
  • Website https://www.pfizer.com
  • Industry Drug Manufacturers - General
  • CEO Albert Bourla
  • Employees 81000

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.